NASDAQ$TARS
Tarsus Pharmaceuticals Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Tarsus reported financial results for the first quarter ended March 31, 2023, and recent business achievements.
Tarsus Pharmaceuticals reported a net loss of $23.4 million for the first quarter of 2023. License fee and collaboration revenue was $2.5 million, while research and development expenses were $12.4 million, and general and administrative expenses were $15.1 million. Cash, cash equivalents and marketable securities totaled $201.2 million as of March 31, 2023.
- Net loss for the first quarter of 2023 was $23.4 million, compared to a net loss of $20.2 million for the same period in 2022.
- License fee and collaboration revenue was $2.5 million, compared to $0.5 million for the same period in 2022.
- Research and development expenses were $12.4 million, compared to $12.1 million for the same period in 2022.
- Cash, cash equivalents and marketable securities were $201.2 million as of March 31, 2023.
Headline financials
Revenue & EPS history
Tarsus · Revenue · Quarterly
$2.5M
Forward guidance
Tarsus is preparing for the potential launch of TP-03 in the fall and advancing its broad pipeline into proof-of-concept studies. Enrollment is ongoing in the Phase 2a rosacea trial of TP-04, and the company remains on-track to provide readouts from Phase 2a trials in Lyme disease prevention and Meibomian Gland Disease.
Tailwinds
- Potential approval and commercialization of TP-03 for the treatment of Demodex blepharitis.
- Advancing pipeline to address diseases with high unmet need.
- Ongoing Phase 2a rosacea trial of TP-04.
- On-track to provide readouts from Phase 2a trials in Lyme disease prevention and Meibomian Gland Disease.
- Salesforce infrastructure in place, ready for potential TP-03 launch.
Headwinds
- Significant losses and negative cash flows from operations since inception.
- May need to obtain additional funding to complete development and commercialization of product candidates.
- Heavily dependent on the success of TP-03 for the treatment of Demodex blepharitis.
- COVID-19 pandemic may affect ability to initiate and complete studies and trials.
- Market opportunity for product candidates may be smaller than estimated.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+3.2%
Avg return
Earnings day
+4.2%
Avg return
5 days after
+17.8%
Avg return
30 days after
63%
15 / 24 earnings
Positive
+18.3%
Q2 2024
Best reaction
-10.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -8.4% | -9.0% | |
| Q4 2025 | +9.6% | +8.5% | -3.4% | |
| Q3 2025 | -4.7% | +1.8% | +14.4% | |
| Q1 2025 | -6.1% | -5.9% | -14.6% | |
| Q4 2024 | -9.3% | -2.3% | +11.2% | |
| Q3 2024 | -1.9% | -6.2% | +10.4% | |
| Q2 2024 | +18.3% | +16.5% | +34.8% | |
| Q1 2024 | -10.5% | +0.9% | -15.3% | |
| Q4 2023 | +14.2% | +11.4% | +9.6% | |
| Q3 2023 | +5.6% | +8.3% | +4.5% | |
| Q2 2023 | -2.5% | -1.5% | -7.0% | |
| Q1 2023 | +7.1% | +5.8% | +25.9% | |
| Q4 2022 | +0.4% | -10.6% | -15.8% | |
| Q3 2022 | -0.1% | -0.5% | -14.2% | |
| Q2 2022 | +5.4% | +0.6% | -8.3% | |
| Q1 2022 | +7.2% | +16.8% | +25.4% | |
| Q4 2021 | -4.9% | -4.7% | -1.1% | |
| Q3 2021 | +0.4% | -2.9% | -13.8% | |
| Q2 2021 | +6.2% | +3.7% | +13.3% | |
| Q1 2021 | +2.9% | +5.6% | +38.3% | |
| Q4 2020 | +16.4% | +15.8% | +8.6% | |
| Q1 2020 | +7.5% | +16.1% | +111.4% | |
| Q3 2020 | +7.5% | +16.1% | +111.4% | |
| Q2 2020 | +7.5% | +16.1% | +111.4% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro